NSCLC Patient Insights You Can't Afford to Ignore! A DelveInsight Case Study - How One Biopharma Company Gained a First-Mover Advantage in NSCLC

DelveInsight, a global leader in healthcare market intelligence and consulting, has successfully partnered with a top-tier biopharmaceutical company specializing in oncology to provide an advanced epidemiology forecasting analysis of Non-Small Cell Lung Cancer (NSCLC). This comprehensive study focused on biomarker-specific segmentation to support strategic drug development, identify target patient populations, and optimize market access planning across global markets.

With the increasing complexity of NSCLC treatment, biomarker-driven therapies have emerged as a critical strategy to enhance clinical outcomes. DelveInsight's tailored epidemiology approach enabled the client to leverage actionable insights, helping them make informed decisions across clinical, regulatory, and commercial domains.

Client Overview
The client, a leading biopharmaceutical company with a strong focus on oncology research and innovation, approached DelveInsight to gain precise epidemiological insights for NSCLC. Their primary objectives included:
• Obtaining biomarker-specific epidemiology data to identify target patient populations.
• Developing long-term incidence forecasts aligned with clinical trial and drug commercialization timelines.
• Supporting market access strategies by evaluating country-wise disease prevalence and patient demographics.
• Identifying emerging and rare genetic mutations for new therapeutic opportunities.
NSCLC represents a significant unmet need in oncology, with numerous genetic mutations driving disease heterogeneity. Understanding the prevalence of biomarkers such as PD-L1, KRAS, EGFR, BRAF, NTRK, and others is crucial for precision medicine approaches, clinical trial design, and targeted therapeutic interventions.

Discover how biomarker-specific epidemiology forecasting can optimize your drug development strategy. Access insights now! - https://www.delveinsight.com/case-study/nsclc-epidemiology-forecasting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Challenges Faced by the Client
Despite having robust clinical development expertise, the client faced several challenges that limited their ability to make fully informed decisions:
1. Limited Biomarker-Specific Data:
Most available data lacked granularity in terms of biomarker prevalence, limiting the ability to accurately segment NSCLC patients by genetic mutations or protein expressions. Critical biomarkers such as PD-L1, KRAS, EGFR, BRAF, and NTRK required precise population estimates.
2. Regional Epidemiology Needs:
The client required country-specific epidemiological insights across the United States, EU4 (Germany, France, Italy, Spain), the UK, and Japan (7MM). Regional variation in disease prevalence, patient journey, and treatment adoption significantly impacts commercial planning and regulatory strategy.
3. Long-Term Forecasting Requirements:
Aligning epidemiological forecasts with clinical trial timelines and potential market entry (2020-2034) required a dynamic forecasting model capable of accounting for demographic shifts, testing adoption, and evolving treatment patterns.
4. Exploring Emerging Mutations:
The company aimed to identify opportunities in rare or hard-to-treat gene fusions and protein expressions that remain largely unexplored by the pharmaceutical industry. This required in-depth research and validated forecasting to inform future therapeutic development.

Get Your Custom NSCLC Forecast - Unlock precise, country-specific patient population data tailored to your therapeutic targets. Request your personalized report today - https://www.delveinsight.com/case-study/nsclc-epidemiology-forecasting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's Strategic Approach
DelveInsight employed a multi-pronged methodology combining real-world evidence, primary research, and advanced analytics to deliver precise and actionable epidemiology insights.
1. Data Collection & Analysis
DelveInsight integrated multiple sources of information to ensure the robustness of the forecasting model:
• Cancer Registries & Government Data: National and regional registries provided incidence, prevalence, and stage-specific data.
• Peer-Reviewed Publications & Clinical Studies: Meta-analyses of published literature ensured coverage of emerging biomarkers and clinical trends.
• Real-World Evidence (RWE): Treatment patterns, biomarker testing adoption, and outcomes data enriched the predictive accuracy of the model.
• Key Opinion Leader (KOL) Engagement: Interviews and surveys with oncology experts validated assumptions, particularly for rare biomarkers and emerging mutations.

2. Granular Disease Segmentation
The epidemiology analysis focused on key dimensions to deliver a nuanced understanding of the NSCLC patient population:
Total NSCLC Incident Cases (US, 2024):
• Approximately 204,000 new cases.
• Men: ~115,000 cases.
• Women: ~89,000 cases.
Age-Specific Analysis:
• Patients aged ≥65 years: ~140,000 cases.
• Emphasized the importance of targeting elderly populations in clinical trial designs.
Histological Subtype Breakdown:
• Adenocarcinoma: ~59% of cases.
• Squamous cell carcinoma: ~25%.
• Large cell carcinoma: ~6%.
Biomarker-Specific Incidence:
• PD-L1: Most prevalent biomarker among NSCLC patients.
• KRAS: Subdivided into KRAS G12C (~4,900 US cases) and KRAS non-G12C (~13,300 US cases).
• EGFR, BRAF: Moderately prevalent (~5% of cases).
• NTRK1/2/3 fusions: Rare (~450 US cases).
• MET alterations: Included MET exon 14 skipping, MET amplification, and cMET overexpression.
• Other biomarkers: TIGIT expression, HER2 mutations and overexpression, ROS1 alterations.
Stage-Specific Analysis:
• Stage I & II: ~35% of diagnosed patients.
• Stage IIIB & IV: ~50% of patients.
• Insights informed the commercial opportunity for early-stage interventions versus late-stage treatments, guiding drug development priorities.

3. Custom Forecast Model (2020-2034)
DelveInsight developed a dynamic forecasting model tailored to the client's needs, enabling long-term strategic planning:
• Demographic Adjustments: Considered aging population trends and regional smoking prevalence.
• Advancements in Genetic Testing: Factored in adoption rates of biomarker testing and screening programs.
• Treatment Evolution: Incorporated the impact of emerging therapies and guideline changes.
• Country-Specific Variations: Adjusted projections for US, EU4, UK, and Japan markets, providing granular insights into regional disease trends.
The result was a robust, evergreen model capable of guiding clinical trial enrollment, market access planning, and commercialization strategies over the next 15 years.

Leverage DelveInsight's forecasting model to identify target populations and accelerate trial enrollment. Request your demo - https://www.delveinsight.com/case-study/nsclc-epidemiology-forecasting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Actionable Insights Delivered to the Client
The epidemiology study provided critical intelligence across multiple domains:
1. Strategic Clinical Trial Planning:
• Identified emerging biomarker targets to optimize clinical trial enrollment.
• Enabled focused patient recruitment for trials in rare and hard-to-treat populations.
2. Market Expansion Strategy:
• Prioritized countries for drug launch based on biomarker distribution trends.
• Informed regional commercial resource allocation to maximize market penetration.
3. Regulatory & Commercial Decision-Making:
• Supported label expansion discussions by providing evidence-based prevalence data.
• Assisted in payer negotiations by quantifying patient populations for specific biomarkers.
4. Exploration of Emerging Opportunities:
• Highlighted unmet needs in rare genetic mutations and protein expressions.
• Offered insights into therapeutic gaps, enabling early-stage investment decisions.

Gain actionable intelligence on emerging mutations and treatment opportunities. Schedule a consultation with our experts now - https://www.delveinsight.com/case-study/nsclc-epidemiology-forecasting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Impact & Results
The partnership between DelveInsight and the client yielded measurable outcomes:
Enhanced Drug Development Strategy:
• Optimized patient enrollment criteria for NSCLC biomarker-driven trials.
• Reduced clinical trial timeline risks by anticipating patient population availability.

Informed Market Access Plans:
• Tailored commercialization strategies by geography and biomarker prevalence.
• Supported pricing strategy discussions with payers based on real-world incidence trends.

Competitive Positioning:
• Gained a first-mover advantage in biomarker-specific NSCLC therapies.
• Positioned the company as a leader in precision oncology, with data-driven evidence supporting market differentiation.

Long-Term Strategic Benefits:
• Provided a repeatable, dynamic forecasting model that can be updated with emerging data.
• Established a foundation for future research, acquisition decisions, and portfolio optimization.

Access data-driven insights to inform pricing, launch, and commercialization strategies for NSCLC therapies. Download the case study here - https://www.delveinsight.com/case-study/nsclc-epidemiology-forecasting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's biomarker-specific NSCLC epidemiology forecasting empowered the client with unparalleled data-driven insights. By combining advanced analytics, primary research, and global datasets, the client was able to refine their drug development and commercialization strategy, ensuring better patient outcomes and strategic business growth.
The success of this project underscores the critical role of precision epidemiology in modern oncology drug development. Companies that leverage biomarker-specific data gain a competitive edge in identifying target populations, optimizing clinical trials, and maximizing market opportunities.

Gain Similar Insights
DelveInsight offers comprehensive NSCLC epidemiology-based market reports, providing detailed analysis of disease prevalence, incidence, patient demographics, and biomarker trends. Companies can access actionable intelligence to drive research, clinical development, and commercialization decisions.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading business consulting and market research firm focused on delivering end-to-end solutions across the pharmaceutical and biotech industries. Our expertise spans market forecasting, competitive intelligence, epidemiology, asset prioritization, licensing support, and R&D strategy.

This release was published on openPR.